AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation

AstraZeneca lung cancer drug Tagrisso (osimertinib) for the treatment of non-small cell lung cancer (NSCLC) in a first line setting has been granted the breakthrough therapy designation by the by the US Food and Drug Administration.

AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation

Pharma news updates : Tagrisso (osimertinib), the AstraZeneca lung cancer drug has bagged the breakthrough therapy designation (BTD) from the US FDA for the treatment of non-small cell lung cancer (NSCLC) in a first line setting. The BTD designation for the AstraZeneca cancer drug is specifically for treating metastatic NSCLC patients who have tested positive […]

Merck lung cancer drug Keytruda plus chemo gets FDA approval for NSCLC

Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease.

Merck lung cancer drug Keytruda plus chemo gets FDA approval for NSCLC

Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease. The Keytruda chemotherapy combination has been approved to treat metastatic non-squamous non small cell lung […]

Novartis lung cancer drug Zykadia gets US FDA priority review

Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions.

Novartis lung cancer drug Zykadia gets US FDA priority review

Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions. The expanded use is for metastatic non-small cell lung cancer (NSCLC) patients whose tumors were detected by an approved FDA test […]

Lung cancer drug Oncoprex phase II trial : Genprex reports positive interim data results

Lung cancer drug Oncoprex phase II trial : Genprex reports positive interim data results

Texas based bio-pharma Genprex has announced positive interim data from an ongoing phase II clinical trial of its lung cancer drug candidate Oncoprex. Titled as NCT01455389, the phase II trial of Oncoprex is evaluating the investigational immunogene therapy drug candidate in combination with erlotinib (Tarceva), a tyrosine kinase inhibitor (TKI) in patients with late stage […]

Smokers with Diabetes have high risk of early death!

Smokers with Diabetes have high risk of early death!

As per the recent study by Kavita Garg, an Indian-origin researcher at the University of Colorado-Denver in US, diabetic persons with heavy smoking habit have double the risk of early death. Diabetes is a chronic health disease with high blood glucose levels. Diabetic people also face many other health complications. Kavita Garg, Professor at the […]